REVANCE THERAPEUTICS INC (RVNC) Stock Price, Quote, News and Overview
NASDAQ:RVNC - Nasdaq - US7613301099 - Common Stock - Currency: USD
RVNC Quote, Performance and Key Statistics
3.65
+0.01 (+0.27%)
The current stock price of RVNC is 3.65 USD. In the past month the price increased by 5.19%. In the past year, price decreased by -38.24%.
RVNC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 51.87 | 676.59B | ||
| JNJ | JOHNSON & JOHNSON | 15.22 | 367.98B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 19.24 | 298.97B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.57 | 222.69B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.93 | 218.30B | ||
| MRK | MERCK & CO. INC. | 9.96 | 195.22B | ||
| PFE | PFIZER INC | 7.26 | 132.26B | ||
| SNY | SANOFI-ADR | 13.57 | 127.25B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.38 | 95.34B | ||
| GSK | GSK PLC-SPON ADR | 7.02 | 78.23B | ||
| ZTS | ZOETIS INC | 27.01 | 72.52B | ||
| HLN | HALEON PLC-ADR | 22.73 | 50.23B |
Related stock screener links
About RVNC
Company Profile
Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The company is headquartered in Nashville, Tennessee and currently employs 597 full-time employees. The company went IPO on 2014-02-06. The firm's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. The company has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The firm has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.
Company Info
REVANCE THERAPEUTICS INC
1222 Demonbreun Street, Suite 2000
Nashville TENNESSEE 37203 US
CEO: Mark J. Foley
Employees: 597
Phone: 16157247755
REVANCE THERAPEUTICS INC / RVNC FAQ
What is the stock price of REVANCE THERAPEUTICS INC today?
The current stock price of RVNC is 3.65 USD. The price increased by 0.27% in the last trading session.
What is the ticker symbol for REVANCE THERAPEUTICS INC stock?
The exchange symbol of REVANCE THERAPEUTICS INC is RVNC and it is listed on the Nasdaq exchange.
On which exchange is RVNC stock listed?
RVNC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for REVANCE THERAPEUTICS INC stock?
15 analysts have analysed RVNC and the average price target is 5.25 USD. This implies a price increase of 43.76% is expected in the next year compared to the current price of 3.65. Check the REVANCE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is REVANCE THERAPEUTICS INC worth?
REVANCE THERAPEUTICS INC (RVNC) has a market capitalization of 381.02M USD. This makes RVNC a Small Cap stock.
How many employees does REVANCE THERAPEUTICS INC have?
REVANCE THERAPEUTICS INC (RVNC) currently has 597 employees.
What are the support and resistance levels for REVANCE THERAPEUTICS INC (RVNC) stock?
REVANCE THERAPEUTICS INC (RVNC) has a support level at 3.64 and a resistance level at 3.69. Check the full technical report for a detailed analysis of RVNC support and resistance levels.
Is REVANCE THERAPEUTICS INC (RVNC) expected to grow?
The Revenue of REVANCE THERAPEUTICS INC (RVNC) is expected to grow by 12.8% in the next year. Check the estimates tab for more information on the RVNC EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy REVANCE THERAPEUTICS INC (RVNC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RVNC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RVNC, evaluating the profitability, health, valuation and growth aspects
- REVANCE THERAPEUTICS INC (RVNC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- REVANCE THERAPEUTICS INC (RVNC) Sales and EPS estimates to see what analysts future expectations are.
- REVANCE THERAPEUTICS INC (RVNC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- REVANCE THERAPEUTICS INC (RVNC) Insider and Institutional Ownership to learn about the owners and their transactions.
- REVANCE THERAPEUTICS INC (RVNC) Stock Chart to make your own analysis
- REVANCE THERAPEUTICS INC (RVNC) Latest news and press-releases to stay up to date.
Does REVANCE THERAPEUTICS INC (RVNC) stock pay dividends?
RVNC does not pay a dividend.
When does REVANCE THERAPEUTICS INC (RVNC) report earnings?
REVANCE THERAPEUTICS INC (RVNC) will report earnings on 2025-03-04, after the market close.
What is the Price/Earnings (PE) ratio of REVANCE THERAPEUTICS INC (RVNC)?
REVANCE THERAPEUTICS INC (RVNC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.93).
RVNC Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to RVNC. When comparing the yearly performance of all stocks, RVNC is a bad performer in the overall market: 86.55% of all stocks are doing better.
RVNC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RVNC. RVNC may be in some trouble as it scores bad on both profitability and health.
RVNC Financial Highlights
Over the last trailing twelve months RVNC reported a non-GAAP Earnings per Share(EPS) of -1.93. The EPS increased by 53.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -39.96% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
RVNC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 71% to RVNC. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of 57.03% and a revenue growth 12.8% for RVNC